Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Weighted Average and Diluted) (2023 - 2024)

Contineum Therapeutics (CTNM) has 2 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.75 in Q4 2024.

  • For Q4 2024, EPS (Weighted Average and Diluted) fell 137.07% year-over-year to -$0.75; the TTM value through Dec 2024 reached -$0.75, changed N/A, while the annual FY2025 figure was -$2.17, 0.46% changed from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.75 in Q4 2024 per CTNM's latest filing, down from -$0.4 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.03 in Q4 2023 and bottomed at -$2.69 in Q3 2023.